Immix Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMX research report →
Range $20 – $25
Price Chart
About the company
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases.
- CEO
- Ilya Rachman
- IPO
- 2021
- Employees
- 21
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on IMMX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $583.33M
- P/E
- -8.39
- Fwd P/E
- 4.94
- PEG
- 0.99
- P/S
- 0.00
- P/B
- 1.54
- EV/EBITDA
- -5.68
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -24.93%
- ROIC
- -14.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-29,956,415
- Net Income
- $-29,438,613-36.2%
- EPS
- $-0.89-17.1%
- OCF Growth
- -64.0%
- FCF Growth
- -56.4%
- 52W High
- $15.10
- 52W Low
- $3.78
- 50D MA
- $9.25
- 200D MA
- $9.64
- Beta
- 0.11
- RSI (14)
- 36
- Avg Volume
- 1.45M
No earnings-call transcripts are available for IMMX yet.
- Free Float
- 70.3%
- Shares Outstanding
- 83.81M
- Float Shares
- 58.91M
of shares held by institutions
114 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 12.07M | ▲ 12.07M |
| Jupiter Topco LLC | 9.78M | ▲ 9.78M |
| Eventide Asset Management, LLC | 5.19M | ▲ 1.30M |
| Saturn V Capital Management LP | 4.66M | ▲ 2.69K |
| Blackrock, Inc. | 4.54M | ▲ 1.55M |
| State Street Corp | 3.30M | ▲ 307.45K |
| Vanguard Capital Management LLC | 3.00M | ▲ 494.88K |
| Opaleye Management Inc. | 2.83M | ▲ 480.00K |
| Balyasny Asset Management L.P. | 2.64M | ▲ 2.23M |
| Ameriprise Financial Inc | 1.86M | ▲ 1.34M |
| Marshall Wace, Llp | 1.85M | ▲ 59.31K |
| Franklin Templeton Inc | 1.79M | ▲ 818.18K |
Held by 130 ETFs
Biggest fund positions in IMMX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Rachman Ilya M | buy | 1,408.45 |
| Nov 18, 26 | Morris Gabriel S | buy | 1,418 |
| May 22, 26 | Adams Helen C. | other | 6,250 |
| May 22, 26 | Adams Helen C. | other | 12,500 |
| May 22, 26 | Ng Carey | other | 6,250 |
| May 22, 26 | Ng Carey | other | 12,500 |
| May 22, 26 | Marquet Magda | other | 6,250 |
| May 22, 26 | Marquet Magda | other | 12,500 |
| May 22, 26 | Morris Gabriel S | other | 500,000 |
| May 22, 26 | CHANG NANCY T | other | 6,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMMX coverage
Recent articles, reports, and earnings notes.
No research on IMMX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMMX report →Aberdeen Group plc Buys New Shares in Immix Biopharma, Inc. $IMMX
defenseworld.net · Nov 20
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
globenewswire.com · Nov 12
Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
globenewswire.com · Nov 4
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
globenewswire.com · Oct 5
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
defenseworld.net · Oct 5
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
marketbeat.com · Oct 4
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
globenewswire.com · Sep 30
Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy?
defenseworld.net · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.